

## DAFTAR PUSTAKA

- AAO, 2013. *Lens and Cataract*. 13th ed. San Francisco: The Eye MD Association.
- Aaberg, TM., Flynn, HW., Schiffman, J. et al., 1998. Nosocomial acute-onset postoperative endophthalmitis survey; a 10 year review of incidence and outcomes. *Ophthalmol*, 105, pp.1004-10.
- AAO, 2017. *External Eye Disease and Cornea*. 17th ed. San Francisco: The Eye MD Association.
- Amer, AK. & Saif, SY., 2013. Safety of prophylactic intracameral moxifloxacin during phacoemulsification. *J of Amr Sci*, 9(6), pp.14-27.
- Arbisser LB., 2009. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. *J Cataract Refract Surg*, 34, pp.1114-20.
- Asena, L., Akova, YA., Goktas, MT., Bozkurt, A., Yasar, U. et al., 2013. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model . *Curr Eye Resl*, 38, pp.472-79.
- Ashok Garg, J.D.S.E.D.D.M.F., 2007. *Clinical Applications of Antibiotics and Anti-inflammatory Drugs in Ophthalmology*. 1st ed. india: Jaypee Brothers.
- Ashok Garg, J.D.S.E.D.D.M.F., 2013. *Handbook of Ocular Therapeutics*. 3rd ed. india: Jaypee Brothers.
- Badan Penelitian dan Pengembangan Kesehatan, 2013. *Riset Kesehatan Daerah (RISKESDAS)*. Kementerian Kesehatan RI.
- Barry, AS. & Eduardo, A., 2005. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (Vigamox®). *J Surv of Ophthalmol*, 50(1), pp.S7-15.
- Bispo, PJM., Alfonso, EC., Flynn, HW. & Miller, D., 2013. Emerging 8-methoxyfluoroquinolone resistance among methicilin susceptible staphylococcus epidermidis isolates recovered from patients with endophthalmitis. *J Clin Microbiol*, 51, pp.2959-65.
- Caeiro, JP. & Lannini, PB., 2003. Moxifloxacin: a novel fluoroquinolone with a broad spectrum of activity. *Expert Rev Anti Infect Ther*, 1, pp.363-70.
- Carbonell, V. & Espiritu, G., 2014. Follow-up study on the safety of prophylactic intracameral administration of moxifloxacin 0.5% ophthalmic solution in cataract surgery. *Phillip J Ophthalmol*, 39, pp.179-85.
- Carrim, ZI., Mackie, G. & Gallacher, G., 2009. The efficacy of 5% povidone-iodine for 3 minutes prior to cataract surgery. *Eur J Ophthalmol*, 19, pp.560-64.
- Cervantes-Coste, G., Sanchez-Castro, Y. & Orozco-Carroll, M., 2009. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. *Clin Ophthalmol*, 2009, pp.219-26.
- Chang, DF., Braga-Mele, R., Mamalis, N., Masket, S., Miller, KM. et al., 2007. Prophylaxis of postoperative endophthalmitis after cataract surgery:

- results of the 2007 ASCRS member survey. *J Cataract Refract Surg*, 33, pp.1801-05.
- Cochereau, IA., Giraudet, S. & Lamirel., 2009. Corneal and retinal tolerance of intracameral cefuroxime in phacoemulsification. *Eye*, 10, pp.3-7.
- Craig, WA., 1998. Pharmacokinetic / pharmacodynamic parameters : rationale for antibacterial dosing of mice and men. *Clin Inf Dis*, 26, pp.1-2.
- Delyfer, MN., Rougier, MB., Leoni, S., Zhang, Q., Dalbon F. et al., 2011. Ocular toxicity after intracameral injection of very high dose of cefuroxime during cataract surgery. *J Cataract Refract Surg*, 37(2), pp.271-78.
- DelMonte, DW. & Kim, T., 2011. Anatomy and physiology of the cornea. *J Cataract Refract Surg*, 37, pp.588-9.
- Diez, MR., De La Rosa, G. & Pascual, R., 2009. Prophylaxis of post operative endophthalmitis with intracameral cefuroxime: a five years experience. *Arch Soc Esp Ophthalmol*, 84(2), pp.85-90.
- Edelhauser, HF., 2006. The balance between corneal transparency and edema; the proctor lecture. *Invest Ophthalmol Vis Sci*, 47, pp.1755-67.
- ESCRS Endophthalmitis Study Group., 2007. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. *J Cataract Refract Surg*, 33, pp.978-88.
- Espiritu, CRG., Caparas, VL. & Bolinao, JG., 2007. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. *J Cataract Refract Surg*, 33, pp.1790-1800.
- Fintelman, RE. & Naseri, A., 2010. Prophylaxis of postoperative endophthalmitis following cataract surgery. *Drugs*, 70(11), pp.1395-1409.
- Fiscella, G., Holdeman, R. & Prokopich, C, 2008. *Anti Infective Drugs in Clinical Ocular Pharmacology*. 5th ed. Missouri: Butterworth-Heinemann Inc.
- Gipson, IK. & Joyce, NC., 2000. *Anatomy and cell biology of the cornea, superficial limbus, and conjunctiva, in Principles and Practice of Ophthalmology*. 1 st ed Philadelphia: WB Saunders Company.
- Halachimi-Eyal, O., Lang, Y. & Kennes, Y., 2009. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac. *J Cataract Refract Surg*, 35, pp.2109-14.
- Haruki, T., Miyazaki, D., Matsuura, K., Terasaka, Y., Noguchi, Y. et al., 2014. Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro. *J Cataract Refract Surg*, 40, pp.1872-78.
- Herrington, LJ., Shorstein, NH. & Paschal, JF. et al., 2016. Comparative effectiveness of antibiotic prophylaxis in cataract surgery. *J of Ophthalmol*, 123, pp.287-94.
- Holzer, MP., Tetz, MR. & Auffarth, GU., 2001. Effect of healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery. *J Cataract Refract Surg*, 27, pp.213-18.

- Hwang, DG., 2004. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. *Surv Ophthalmol*, 49(2), pp.79-83.
- Keating, MG., 2013. Intracameral cefuroxime; prophylaxis of postoperative endophthalmitis after cataract surgery. *Drugs*, 73, pp.179-186.
- Kernt, M., Neubauer, AS., Liegl, RG., Lackerbauer, CA., Eibl, KH. et al., 2009. Intracameral moxifloxacin: in vitro safety on human ocular cells. *Cornea*, 28(5), pp.553-61.
- Kim, DH., Stark, WJ., O'Brien, TP. & Dick, JD., 2005. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. *Ophthalmol*, 112, pp.1992-26.
- Konomi, K., Zhu, C., Harris, D. & Joyce, NC., 2005. Comparison of the proliferative capacity of human corneal endothelial cells from the central and peripheral areas. *Invest Ophthalmol Vis Sci*, 46, pp.4086-91.
- Kowalski, RP., Dhaliwal, DK. & Karenchak, LM., 2003. Gatifloxacin and moxifloxacin : an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. *Am J Ophthalmol*, 136, pp.500-05.
- Kramann, C., Pitz, S. & Schwenn, O., 2001. Effects of intraocular cefuroxime on human corneal endothelium. *J Cataract Refract Surg*, 27, pp.250-55.
- Lane, S., Osher, H., Masket, S. & Belani, S., 2008. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. *J Cataract Refract Surg*, 34, pp.1451-59.
- Malik, R., UI Haq, S. & Rahil, N., 2011. *Efficacy trial of intracameral cefuroxime vs moxifloxacin as prophylaxis of acute post operative endophthalmitis in cataract surgery*. *Ophthalmol Update*, 9(4), pp.102-05.
- Malik, VK., Kapoor, R., Malik, KPS., Kumar, S., Jain, C. et al., 2016. Effect of intracameral moxifloxacin (0.5 mg) on morphology and cell density of corneal endothelium in phacoemulsification surgery. *Del J Ophthalmol*, 27(2), pp.324-33.
- Mamalis, MD., Edelhauser, HF., Dawson, G. et al., 2006. Toxic anterior segment syndrome. *J Cataract Refract Surg*, 32, pp.324-33.
- Masket, S., 1998. Preventing, diagnosing, and treating endophthalmitis. *J Cataract Refract Surg*, 24, pp.725-26.
- Matsumoto, S., Way, W., Carlo, K. & Short, B., 2006. Comparative toxicity of fluoroquinolones antibiotics on corneal cells in vitro. *Cornea*, 25, pp.1-7.
- Matsuura, K., Miyoshi, T., Suto, C., Akura, J. & Inoue, Y., 2013. Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentration and drug kinetics. *Graefes Arch Clin Exp Ophthalmol*, 251, pp.1955-59.
- McColgin, A. & Raizman, M., 1999. Efficacy of topical Voltaren in reducing the incidence of post operative cystoid macular edema. *Invest Ophthalmol Vis Sci*, 40, p.S289.

- McCulley, JP., Caudle, D., Aronowicz, JD. & Shine, WE., 2006. Fourth generation fluoroquinolone penetration into the aqueous humor in humans. *Ophthalmol*, 113, pp.955-59.
- Mehta, S., Armstrong, BK., Kim, SJ., Toma, H., West, JN. et al., 2011. Long term potency, sterility, and stability of vancomycin, ceftazidime, and moxifloxacin for treatment of bacterial endophthalmitis. *Retina*, 31, pp.1316-22.
- Montan, PG., Wejde, G., Koranyi, G. & Raylander, M., 2002. Prophylactic intracameral cefuroxime; efficacy in preventing endophthalmitis after cataract surgery. *J Cataract Refract Surg*, 28, pp.977-81.
- Moisseiev, E. & Levinger, E., 2013. Anaphylactic reaction following intracameral cefuroxime injection during cataract surgery. *J Cataract Refract Surg*, 39, pp.1432-34.
- Moshirfar, M., Feiz, V. & Vitale, AT., 2007. Endophthalmitis after uncomplicated cataract surgery with the use of fourth generation fluoroquinolones: a retrospective observational case series. *Ophthalmol*, 114, pp.686-91.
- Nguyen, TE., Pharm, D. & Shorstein, HN., 2013. Preparation of intracameral antibiotics. *J Cataract Refract Surg*, 39, pp.1788-8.
- O'Brien, TP., Arshinoff, SA. & Mah, FS., 2007. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. *J Cataract Refract Surg*, 33, pp.63-68.
- Olavi, P., 2012. Ocular toxicity in cataract surgery because of inaccurate preparation and erroneous use of 50 mg/ml intracameral cefuroxime. *Acta Ophthalmol*, 90(2), pp.153-54.
- Osmon, D., 2000. Antimicrobial prophylaxis in adults. *Mayo Clin Proc*, 75, pp.98-109.
- Ozlem, TY., Necati, DM. & Fatma, YM., 2010. Are cefuroxime and vancomycin really safe on the corneal endothelial cells. *Graefes Arch Clin Exp Ophthalmol*, 248(3), pp.415-20.
- Packer, M., Chang, D. & Steven, H., 2011. Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. *J Cataract Refract Surg*, 37, pp.1699-14.
- Peyman, GA., Sathar, ML. & May, DR., 1977. Intraocular gentamicin as intraoperative prophylaxis in south india eye camps. *Br J Ophthalmol*, 61, pp.260-62.
- Pickerill, KE., Paladino, JA. & Schentag, JJ., 2000. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. *Pharmacotherapy*, 20, pp.417-28.
- Rahman, N. & Murphy, C., 2015. Impact of intracameral cefuroxime on the incidence of postoperative endophthalmitis following cataract surgery in ireland. *J Med Sci*, 184, pp.395-98.
- Rigal, S., Mullot, H., Mullot, J., Sgarioto, A., Huart, B. et al., 2008. Intracameral cefuroxime: evaluation of stability in normal saline and balance salt solution. *Acta Ophthalmol*, 86, pp.243-53.
- Samuel Gnanadoss., 2008. *Manual of Cornea*. 1st ed. india: Jaypee Brothers.

- Schentag, JJ., Gililand, KK. & Paladino, JK., 2001. What we have learned from pharmacokinetic and pharmacodynamic theories?. *Clin Inf Dis*, 32(1), pp.39-46.
- Scott, LJ., Ormrod, D. & Goa, KL., 2001. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. *Drugs*, 61(10), pp.1455-500.
- Schultz, R. O., Glasser, D. B., Matsuda, M., Yee, R. W. & Edelhauser, H. F. 1986. Response of the corneal endothelium to cataract surgery. *Arch of Ophthalmol*, 104, pp.1164-1169.
- Sharma, S., Sahu, K., Dhillon, V., Das, S. & Rath, S., 2015. Reevaluating intracameral cefuroxime as a prophylaxis against endophthalmitis after cataract surgery in india. *J Cataract Refract Surg*, 41, pp.393-99.
- Shihadeh, W., Abdelkader, A. & Kaufman, H., 2010. *Corneal Endothelial Transplant : Corneal Physiology*. 1st ed. india: Jaypee Brothers.
- Simone, J. & Whitacre, M., 2001. Effects of antiinflammatory drugs following cataract extraction. *Curr Opin Ophthalmol*, 12, pp.63-70.
- Taban, M., Behrens, A. & Newcomb, RL., 2005. Acute endophthalmitis following cataract surgery; a systematic review of the literature. *Arch Ophthalmol*, 123, pp.613-20.
- Takács, Á. I., Kovács, I. & Miháltz, K., 2012. Central corneal volume and endothelial cell count following femtosecond laser-assisted refractive cataract surgery compared to conventional phacoemulsification. *J Cataract Refract Surg*, 28, 387-391.
- Tam, ES. & Rootman, DS., 2003. Comparison of central corneal thickness measurements by specular microscopy, ultrasound pachymetry, and ultrasound biomicroscopy. *J Cataract Refract Surg*, 29, pp.1179-84.
- Tang Y., X, C., Zhang, X., Tang, Q., Liu, S. & Yao, K. 2017. Clinical evaluation of corneal in diabetic and non-diabetic cataract patients, a systematic review and meta-analysis *Nature*, 7, 14128.
- Vazirani, J. & Basu, S., 2013. Role of topical, subconjunctival, intracameral,, and irrigative antibiotics in cataract surgery. *Curr Opin Ophthalmol*, 24(1), pp.60-65.
- Walkow, T. & Klebe, S., 2000. Endothelial cell loss after phacoemulsification: relation to preoperative and intraoperative parameters. *J Cataract Refract Surg*, 26(5), pp.727-32.
- Wejde, G., Montan, P. & Lundstrom, M., 2005. Endophthalmitis following cataract surgery in sweden : national prospective survey 1999-2001. *Acta Ophthalmol*, 83, pp.7-10.
- Wolfson, JS. & Hooper, DC., 1985. The fluoroquinolones : structures, mechanisms of action and resistance, and spectra activity in vitro. *Antimicrob Agents Chemother*, 28, pp.581-86.
- Yanoff & Duker., 2015. *Complication of Cataract Surgery in Ophthalmology* . 4th ed. United Kingdom: Mosby Inc.
- Yoeruek, E., Spitzer, MS., Saygili, O., Tatar, O., Biedermann, T. et al., 2008. Comparison of in vitro safety profiles of vancomycin and cefuroxime on

human corneal endothelial cells for intracameral use. *J Cataract Refract Surg*, 34(12), pp.2139-45.